Joinn Laboratories(China)Co.,Ltd. (6127.HK)

HKD 9.01

(-0.99%)

Market Cap (In HKD)

12.48 Billion

Revenue (In HKD)

2.37 Billion

Net Income (In HKD)

396.99 Million

Avg. Volume

875.74 Thousand

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.31-14.3
PE
-
EPS
-
Beta Value
0.655
ISIN
CNE100004BP3
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Dr. Yuxia Feng M.D.
Employee Count
-
Website
https://www.joinn-lab.com
Ipo Date
2021-02-26
Details
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment designs, produces, breeds, and sells research models, non-human primates, and rodents. The company also offers investment management and cell-based assay (CBA) services. Joinn Laboratories(China)Co.,Ltd. was founded in 1995 and is headquartered in Beijing, China.